Trust Signals
- Written by the FormBlends Medical Team with reference to primary literature, not secondary health blogs.
- Every major claim is graded by evidence type in the evidence ledger below.
- No human RCT for 5-amino-1MQ exists in indexed literature as of May 2026. This page says so plainly.
- Mechanism numbers are sourced to named studies. Where numbers cannot be sourced, ranges are used instead.
- This page was updated 2026-05-29 and discloses conflicts of interest: FormBlends does not currently sell 5-amino-1MQ.
Key Takeaways
- The only published dose-response animal study (Jamal et al., 2020, Molecular Metabolism) used subcutaneous injection at roughly 10 mg/kg/day in mice, not oral dosing, making injection the route with slightly more mechanistic grounding, not clinical validation.
- No published human pharmacokinetic data exists for either route, so oral bioavailability comparisons between the two are extrapolation, not measurement.
- 5-amino-1MQ inhibits NNMT, reducing methyl group expenditure on nicotinamide and theoretically raising intracellular SAM availability, a distinct mechanism from NAD+ precursor supplementation.
- Injectable formulations sold outside a licensed compounding pharmacy add endotoxin and sterility risk on top of a wholly unvalidated systemic safety profile.
- Oral capsules are the pragmatic lower-risk default because the added risks of injection are concrete while the bioavailability advantage is unproven in humans.
Direct Answer: Oral or Injection for 5-Amino-1MQ?
No human trial has compared 5-amino-1MQ oral vs injection. The key animal study used subcutaneous injection. Oral capsules dominate current practice because the molecule is small and plausibly absorbed, and because injection adds sterility risk without a proven bioavailability advantage in humans. Evidence for either route remains animal-level only.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What is 5-amino-1MQ and how does it work mechanistically?
- What is the actual evidence quality for 5-amino-1MQ?
- Can 5-amino-1MQ be absorbed orally?
- What did the injection studies actually show?
- What most pages get wrong about 5-amino-1MQ route choice
- Honest head-to-head: oral vs injection vs alternatives
- The chemistry behind stability and storage rules
- Label and COA literacy: how to judge a product yourself
- Dosing table: what is actually being used and what it is based on
- Safety unknowns worth knowing before either route
- FAQ
- Sources
What Is 5-Amino-1MQ and How Does It Work Mechanistically?
5-amino-1-methylquinolinium (5-amino-1MQ) is a small-molecule quinolinium salt with a molecular weight of approximately 174 g/mol. Its primary proposed target is nicotinamide N-methyltransferase (NNMT), an enzyme that transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide, producing 1-methylnicotinamide and S-adenosylhomocysteine (SAH).
Why does inhibiting this enzyme matter? NNMT is highly expressed in adipose tissue and acts as a metabolic drain in two ways. First, it consumes SAM, the cell's primary methyl donor, reducing the pool available for epigenetic methylation and other regulated processes. Second, it diverts nicotinamide away from NAD+ synthesis. Blocking NNMT is therefore proposed to raise intracellular SAM, shift nicotinamide back toward NAD+ production, and alter the epigenetic landscape of adipocytes in ways that reduce lipid storage.
This is a mechanistically coherent hypothesis. It does not, however, prove that a pill or injection in a human produces the same effect in the same tissue at the same magnitude seen in rodent cell lines or mice.
What Is the Actual Evidence Quality for 5-Amino-1MQ?
Below is the evidence ledger. Read the confidence column before acting on any claim.
| Claim | Best Evidence Type | Source / Study | Effect Direction | Confidence |
|---|---|---|---|---|
| 5-amino-1MQ inhibits NNMT in cell culture | In vitro mechanistic | Jamal et al., 2020, Mol Metab | NNMT activity reduced | Moderate (in vitro) |
| Subcutaneous injection reduces fat mass in diet-induced obese mice | Animal RCT | Jamal et al., 2020, Mol Metab | Positive, fat mass reduced | Low (animal only) |
| Raises intracellular SAM in adipocytes | In vitro / animal | Jamal et al., 2020, Mol Metab | SAM levels increased | Low |
| Oral route produces meaningful plasma levels in humans | No human PK data | None published | Unknown | Very Low |
| Injection superior to oral in humans | No comparative human data | None published | Unknown | Very Low |
| Weight loss effect in humans | No human RCT | None published | Unknown | Very Low |
| Long-term safety in humans (either route) | No human safety study | None published | Unknown | Very Low |
Can 5-Amino-1MQ Be Absorbed Orally?
The molecule has properties that are permissive but not confirmatory of oral absorption. At roughly 174 g/mol it is well below the Lipinski 500 g/mol threshold. Its quinolinium core carries a permanent positive charge at physiological pH, which typically reduces passive membrane permeability compared to a neutral or lipophilic molecule. That charge is the key pharmacokinetic question mark.
Charged quaternary nitrogen compounds can still achieve meaningful oral absorption through active transporter-mediated uptake or paracellular routes, but bioavailability varies enormously between molecules in this class. Without a published human Cmax, AUC, or Tmax measurement for 5-amino-1MQ taken orally, claims that it "absorbs well" or "reaches target tissue" after oral dosing are not supported by published data. They are plausible inferences, not established facts.
Rodent studies suggest the compound is orally active at some level (effects have been reported with oral delivery in at least one experimental context), but rodent gut absorption and first-pass metabolism differ substantially from human, and no formal bioavailability percentage has been published for either species.
What Did the Injection Studies Actually Show?
The most cited published study (Jamal et al., 2020 in Molecular Metabolism) treated diet-induced obese mice with 5-amino-1MQ via subcutaneous injection at approximately 10 mg/kg/day. Key reported outcomes included reductions in fat mass, improvements in metabolic parameters, and changes consistent with NNMT inhibition in adipose tissue.
This study is animal data. Translating 10 mg/kg/day in mice to a human equivalent dose using body surface area scaling (the standard FDA preclinical conversion, dividing by a factor of roughly 12 for mouse to human) yields an approximate human equivalent in the low single-digit mg/kg range, but this conversion is a rough regulatory starting point for safety studies, not a dosing prescription. The pharmacodynamics of NNMT inhibition may not scale linearly, and target tissue concentrations are unmeasured in humans at any dose.
There is no published injectable human study. There is no published pharmacokinetic comparison showing that injection achieves higher adipose tissue concentrations than oral dosing in humans or even in rodents at matched systemic doses. The injection advantage is assumed, not demonstrated.
What Most Pages Get Wrong About 5-Amino-1MQ Route Choice
The biggest omission in most 5-amino-1MQ content: Route-of-administration comparisons for this compound are entirely theoretical. No published pharmacokinetic study in humans has measured plasma levels after oral capsule, sublingual, or subcutaneous injection to determine which delivers more compound to adipose tissue. Every recommendation for one route over another is an argument from plausibility or analogy to other quinolinium compounds, not a measurement.
Second omission: the quaternary charge of the molecule means it may be actively effluxed by P-glycoprotein or other transporters at the gut wall, a variable that makes oral bioavailability predictions especially unreliable without direct measurement.
Third omission: injectable 5-amino-1MQ sold as a research chemical has no mandated endotoxin testing requirement. Bacterial lipopolysaccharide contamination in improperly prepared injectables causes fever, systemic inflammation, and in severe cases septic shock. This risk is not theoretical; it is a documented hazard of research chemical injectables and is never mentioned in promotional content.
Honest Head-to-Head: Oral vs Injection vs Alternatives
| Option | Mechanism | Human RCT? | Bioavailability Data | Practical Risk | Honest Assessment |
|---|---|---|---|---|---|
| 5-amino-1MQ oral | NNMT inhibition | None | None published in humans | Unknown systemic profile | Lowest added risk, zero validation |
| 5-amino-1MQ injection | NNMT inhibition | None | None published in humans | Adds endotoxin, sterility risk | More risk, no proven advantage |
| NMN oral | NAD+ precursor | Multiple (Yoshino et al., 2021 Science; others) | Raises blood NAD+ measurably | Low, generally well-tolerated | Wins on evidence quality |
| NR oral | NAD+ precursor | Multiple human RCTs | Raises blood NAD+ measurably | Low, generally well-tolerated | Wins on evidence quality |
| Semaglutide (GLP-1 RA) | GLP-1 receptor agonist | Multiple large RCTs (STEP trials, 17,000+ participants) | Well-characterized PK | Known, manageable GI and other side effects | Far stronger evidence for weight management |
5-amino-1MQ loses to NMN, NR, and approved medications on every evidence metric. That does not rule out a future role once human data exists, but it is the honest current picture.
The Chemistry Behind Stability and Storage Rules
5-amino-1MQ contains an aromatic amine (the amino group at position 5) and a quaternary nitrogen in the quinolinium ring. Both are potential oxidation targets. Aromatic amines are susceptible to oxidation under light exposure and in the presence of dissolved oxygen, producing colored degradation products. This is why authentic powder is off-white to pale yellow; deepening color over time in a solution product is a practical degradation signal.
The quaternary salt is generally hydrolytically stable at neutral pH but can undergo ring-opening or demethylation under strongly acidic or alkaline conditions. Reconstituted solutions stored at room temperature in light have more degradation risk than refrigerated, light-protected preparations. For injectable preparations this matters because degradation products of unknown toxicity are being injected directly. For oral capsules, gastric acid exposure is a separate variable that could affect the intact molecule reaching intestinal absorption sites.
Store oral capsules in a cool, dry, dark location, not in a car or near a window. For any reconstituted solution, refrigerate at 2 to 8 degrees Celsius, protect from light, and discard if color changes noticeably. These are not arbitrary rules; they follow directly from the chemistry of the functional groups.
Label and COA Literacy: How to Judge a Product Yourself
For either route, the minimum acceptable documentation from a supplier is a certificate of analysis (COA) from a third-party laboratory (not the supplier's own lab). Here is what to look for:
| Parameter | What to Look For | Why It Matters |
|---|---|---|
| Identity confirmation | LC-MS or NMR confirming MW approx. 174 g/mol and correct fragmentation pattern | Rules out substitution with a cheaper quinoline analog |
| Purity | HPLC area percent above 98% | Below 95% means meaningful unknown impurities present |
| Heavy metals | Lead, arsenic, cadmium, mercury below USP 232 limits | Quinolinium synthesis can introduce metal catalyst residues |
| Residual solvents | Class 2 and 3 solvents below USP 467 limits | Synthesis may use DCM, DMF, or methanol |
| Endotoxins (injectable only) | LAL (limulus amebocyte lysate) test result below 1 EU/mL | Critical; fever and sepsis risk from contaminated injectables |
| Sterility (injectable only) | USP 71 sterility test passed | Gram-negative bacterial contamination is not visible |
| COA date | Within the last 12 months for the specific lot | Older COAs may not reflect current batch quality |
If a supplier cannot provide a third-party COA with identity confirmation, do not use the product. Appearance alone tells you nothing about purity or identity.
Dosing Table: What Is Actually Being Used and What It Is Based On
The following table reflects doses circulating in research and practitioner communities as of 2026. These are not recommended doses. They are a factual description of what is being used, graded by the quality of the underlying rationale.
| Route | Dose Range in Use | Basis | Evidence Grade |
|---|---|---|---|
| Oral capsule | 50 to 200 mg once daily, commonly 100 mg | Empirical, scaled from animal data with informal clinical observation | Very Low |
| Subcutaneous injection | Not standardized; rarely used outside animal research context | Animal study at approx. 10 mg/kg; human translation unvalidated | Very Low |
| Cycle length | 4 to 8 weeks on, variable off periods | No pharmacological basis; convention borrowed from other peptides | Very Low |
Safety Unknowns Worth Knowing Before Either Route
NNMT has context-dependent roles. It is overexpressed in several cancers including gastric adenocarcinoma, thyroid, and bladder tumors, and in those contexts NNMT inhibition has been proposed as a therapeutic strategy. However, NNMT also regulates methylation balance in non-adipose tissues. Sustained systemic inhibition across multiple tissues in a healthy adult is a pharmacological action whose long-term consequences have not been studied in humans.
The concern is not proven harm. It is proven ignorance. No 90-day human safety study, no liver function or methylation biomarker tracking study, and no drug interaction study has been published. Practitioners using this compound are operating entirely outside the safety envelope established by clinical pharmacology. That is not a reason to assume harm; it is a reason to be honest about what is unknown.
For injection specifically: anyone considering subcutaneous injection of a research chemical should understand that pharmaceutical-grade injectable preparation requires sterile manufacturing conditions that are not guaranteed in research chemical supply chains. The endotoxin risk is real, not theoretical.
FAQ
No human trial has directly compared the two routes. Oral capsules are far more common in practice because 5-amino-1MQ appears to have reasonable oral activity in rodent models, but injection data in humans does not exist in published literature. The practical answer is that oral is the default route used in all available research.
5-amino-1-methylquinolinium (5-amino-1MQ) is a small-molecule inhibitor of the enzyme NNMT (nicotinamide N-methyltransferase). By blocking NNMT, it is proposed to shift cellular NAD+ metabolism toward higher availability and reduce methyl group consumption, potentially influencing fat cell differentiation and metabolic rate.
As of 2026, published human clinical trial data for 5-amino-1MQ does not exist in indexed literature. Evidence is limited to in vitro cell studies and rodent experiments. All human claims are extrapolated from animal data and are Low to Very Low confidence.
Jamal et al. (2020) in Molecular Metabolism used subcutaneous injection in diet-induced obese mice at approximately 10 mg/kg/day and reported reductions in fat mass and improvements in metabolic markers. Human dose equivalents derived by body surface area scaling are speculative and not validated.
The molecule is small (MW roughly 174 g/mol), but its permanent positive charge limits passive permeability. Rodent data suggests oral activity, but formal oral bioavailability studies with Cmax, AUC, and Tmax in humans have not been published. Oral absorption is plausible but unquantified in humans.
5-amino-1MQ is not FDA-approved in any form. Injectable versions are sold by research chemical suppliers or compounding pharmacies operating outside standard approval pathways. Injectable formulations carry additional sterility and endotoxin risks that oral capsules do not. Regulatory status varies by jurisdiction.
Injectable formulations add injection-site reactions, infection risk, and potential endotoxin exposure on top of the unknown systemic safety profile shared by both routes. Oral capsules avoid these local risks but the systemic risk profile is equally undefined because no human safety trial has been completed.
NMN and NR are NAD+ precursors with multiple human RCTs showing they raise blood NAD+ levels. 5-amino-1MQ works upstream by inhibiting NNMT to reduce NAD+ consumption, a different and less-validated mechanism. NMN and NR have substantially more human safety and efficacy data.
Look for HPLC or LC-MS purity above 98%, a confirmed molecular weight or mass spectrum matching 5-amino-1-methylquinolinium at approximately 174 g/mol, heavy metal panel, residual solvent limits per USP 467, and for injectables an endotoxin result (LAL test) below 1 EU/mL.
NNMT is overexpressed in several tumor types including gastric and thyroid cancers, and inhibiting it has been proposed as anti-tumor in those contexts. However, NNMT also has complex context-dependent roles and long-term systemic NNMT inhibition in humans is unstudied. This is a legitimate unresolved safety question, not a proven risk.
Authentic 5-amino-1MQ salt forms are typically off-white to pale yellow powders or solutions. Significant browning, precipitate in solution products, or an unexpected strong odor may indicate degradation or contamination. Without third-party testing you cannot verify identity by appearance alone.
Given that the only published mechanistic animal study used subcutaneous injection but no route-comparison data exists, and oral capsules avoid additional sterility risks, oral is the more pragmatic and lower-risk route for anyone using this research compound. Neither route has validated human efficacy.
Sources
- Jamal A, et al. A small molecule NNMT inhibitor (5-amino-1MQ) promotes weight loss by reducing energy consumption and adipogenesis. Molecular Metabolism. 2020;46:101174.
- Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229.
- Garber K. Drugging NNMT in adipose tissue. Nature Biotechnology. 2016;34:900-901. (context on NNMT biology)
- Campagna R, et al. The enigmatic role of NNMT: a new perspective on its implications in disease. Disease Markers. 2022. (NNMT cancer overexpression context)
- Lipinski CA, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews. 2001;46(1-3):3-26. (molecular property rules)
- US Food and Drug Administration. Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. FDA, 2005. (animal-to-human dose conversion context)
- US Pharmacopeia. USP 232/233 Elemental Impurities. USP-NF, current edition.
- US Pharmacopeia. USP 467 Residual Solvents. USP-NF, current edition.
- US Pharmacopeia. USP 71 Sterility Tests. USP-NF, current edition.